Le Lézard
Classified in: Business, Covid-19 virus
Subject: ERN

Katipult Releases Q2 2020 Results


CALGARY, AB, Aug. 12, 2020 /CNW/ - Katipult Technology Corp. (TSXV: FUND) ("Katipult" or the "Corporation"), provider of an industry leading and award-winning cloud-based software infrastructure for powering the exchange of capital in equity and debt markets, is pleased to announce its financial results for the three and six months ended June 30, 2020.

Q2 Summary











2020

2019

2018

($ Cdn thousands)

 Q2 

 Q1 

 Q4 

 Q3 

 Q2 

 Q1 

 Q4 

 Q3 

Subscription revenue 

329

329

329

365

307

303

251

188

Integration revenue

-

31

53

22

77

160

24

122

Total revenue

329

360

382

387

384

463

275

310

Gross profit 

253

295

312

311

306

377

201

229

Gross profit - percentage

76.9%

81.9%

81.7%

80.4%

79.7%

81.4%

73.1%

73.9%

Selling, general, and administrative

495

517

509

438

447

494

569

463

Research and development

219

182

161

190

212

254

257

222

Adjusted EBITDA 

(325)

(267)

(219)

(242)

(224)

(238)

(511)

(471)

Net income (loss) and   comprehensive income (loss)

(620)

(728)

709

(353)

(343)

(707)

(520)

(596)

"We continue to successfully execute on our plan to move up market as enterprise customers recognize the value of our product offering." said Gord Breese, President and CEO.

About Katipult 
Katipult (www.katipult.com) is a provider of industry leading and award-winning software infrastructure for powering the exchange of capital in equity and debt markets. Our cloud-based platform and solutions digitize investment workflow by eliminating transaction redundancy, strengthening compliance, delighting investors, and accelerating deal flow. Katipult provides unparalleled adaptability for regulatory compliance, asset structure, business model, and localization requirements.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. 

Forward-Looking Statement
Cautionary Note Regarding Forward Looking Statements: Certain disclosure in this release, including statements regarding the increased or continued industry interest in the Corporation's product, converting existing sales interest and installations into revenue, generating new sales opportunities, effectively and efficiently utilizing the Corporation's resource and the ability to deal with business disruptions or opportunities as a result of the Covid-19 pandemic constitute forward-looking statements. In making the forward-looking statements in this release, the Corporation has applied certain factors and assumptions that are based on the Corporation's current beliefs as well as assumptions made by and information currently available to the Corporation, including, but not limited to, the Corporation's anticipated cash needs, that the cash available to the Corporation is as expected, the Corporation's product will continue to operate as expected, the industry will continue to see value in the Corporation's product, the Corporation will be able to recruit talented and experienced sales, support and other individuals required to execute the Corporation's plans, and that the Corporation's employees, consultants, customers, suppliers and other stakeholders will be able to manage successfully throughout the Covid-19 pandemic. Although the Corporation considers these assumptions to be reasonable based on information currently available to it, they may prove to be incorrect, and the forward-looking statements in this release are subject to numerous risks, uncertainties and other factors that may cause future results to differ materially from those expressed or implied in such forward-looking statements. Such risk factors may include, among others, the risk that cash available to the Corporation is not as expected, failure to manage growth successfully, lengthier than anticipated sales and implementation cycle, cyber risks, risks related to cloud based solutions, failure to continue to adapt to technological change and new product development, dependence on key personnel, competition, intellectual property risks, economic conditions, the financial and economic fallout due to the Covid-19 pandemic, privacy concerns and legislation, regulatory environment, risk associated with a change in the Corporation's pricing model, risk of defects in the Corporation's solution, dependence on market growth, operational service risk, dependence on partners and delay or failure to realize anticipated benefits of key account installations. Readers are cautioned, especially in these uncertain times, not to place undue reliance on forward-looking statements. The Corporation does not intend to, and expressly disclaims any intention or obligation to, update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.

SOURCE Katipult Technology Corp.


These press releases may also interest you

at 10:35
Dr. Reddy's Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY) today announced its consolidated financial results for the fourth quarter and full year ended March 31, 2024. The information mentioned in this release is based...

at 10:30
The "Global Legionella Testing Market: Analysis By Type, By Application, By Region Size and Trends with Impact of COVID-19 and Forecast up to 2029" report has been added to ResearchAndMarkets.com's offering. The global legionella testing market has...

at 10:10
The "Global Social Casino Games Market (By Type, Genre, Platform & Region): Insights & Forecast with Potential Impact of COVID-19 (2024-2028)" report has been added to ResearchAndMarkets.com's offering. The global social casino games market is...

at 10:05
As travel will be at historic levels this summer accompanied with rising costs, KLM Royal Dutch Airlines is launching its new brand platform Travel Well to promote and encourage meaningful travel to its 30.3 million passengers flying each year. KLM...

at 10:00
Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced that its self-developed novel Nectin-4-targeting ADC (R&D code: 9MW2821) has been granted Orphan Drug Designation (ODD) by the U.S. Food and...

at 10:00
Economic activity in the hospital subsector grew in April for the eighth consecutive month after contracting twice in the previous four-month period, with 35 consecutive months of growth prior to that, say the nation's hospital supply executives in...



News published on and distributed by: